Home » John Berriman

John Berriman

Jun 05, 2007
Premium
Solexa co-founder John Berriman has become chairman of Belgian biomarker company Pronota, the company said last week. Berriman is also chairman of Algeta and a director at MicroMet, Ablynx, and Oxxon Therapeutics.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Last of the Northern White Rhinoceroses, Sequenced

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

DNA Phenotyping Allowed in Bavaria

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Thanks for the Stress, Dad

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

This Week in Science

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Jun
12
Featured Webinar

Bridging the Gap Between Testing and Treatment in Precision Oncology

Sponsored by
Philips Genomics

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Jun
28
Featured Webinar

An Optimized NGS Workflow for Human Metagenomic Analysis

Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.

What's Popular?

In Clinical Sequencing

  1. Grail Raises $300M in Series C Round

  2. Two Initiatives Seek to Harmonize Tumor Mutational Burden Testing

    Premium

  3. Foundation Medicine's Stock Rises on Approval of Test as New ADLT

  4. Functional Assays Improve Classification of Potential Cystic Fibrosis Risk Variants

  5. Swift Biosciences, Genomenon to Co-Market NGS Panel Design Service

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.